Cue Biopharma, Inc. (CUE) stock
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.83−11.27 (-79.93%)
Close on Nov 17, 2026Market cap $20.56MP/E –Yield –
Cue Biopharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Cue Biopharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$50.05M. For fiscal 2025 it was -$21.69M. The highest annual figure on record is -$12.14M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$21.69M | – |
| FY2024 | Dec 31, 2024 | -$36.33M | – |
| FY2023 | Dec 31, 2023 | -$39.96M | – |
| FY2022 | Dec 31, 2022 | -$41.81M | – |
| FY2021 | Dec 31, 2021 | -$38.84M | – |
| FY2020 | Dec 31, 2020 | -$32.49M | – |
| FY2019 | Dec 31, 2019 | -$30.80M | – |
| FY2018 | Dec 31, 2018 | -$26.41M | – |
| FY2017 | Dec 31, 2017 | -$12.14M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$29.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.94M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.08M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.17M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.03M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.53M | – |
| Q2 FY2024 | Jun 30, 2024 | -$9.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.78M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.80M | – |
| Q2 FY2023 | Jun 30, 2023 | -$10.37M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.83M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.51M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.87M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.85M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.57M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.65M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.63M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.77M | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.80M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.00M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.69M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.86M | – |
| Q1 FY2020 | Mar 31, 2020 | -$10.94M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.44M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.21M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.68M | – |
| Q1 FY2019 | Mar 31, 2019 | -$8.48M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.90M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.30M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.46M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.76M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.85M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.68M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.16M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.46M | – |
See a number that looks wrong?